Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.915 USD | +1.22% | +6.32% | -30.05% |
05-02 | CUREVAC : A missed opportunity | |
04-26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.05% | 645M | |
+24.67% | 46.71B | |
+48.83% | 41.8B | |
-1.30% | 41.52B | |
-3.42% | 29.55B | |
+10.61% | 25.78B | |
-21.30% | 19.26B | |
+0.62% | 12.14B | |
-2.77% | 12.08B | |
+26.74% | 11.98B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers